Focus: Ichnos Sciences, the biotech innovation arm of Glenmark Pharma, focuses on bispecific antibodies targeting cardiovascular, neurology, immunology, women's health, and respiratory indications. The company operates as a mid-sized biotech entity (51-200 employees) based in New York with a hybrid portfolio of commercialized generics and early-stage specialty programs.
Profile data last refreshed 10h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Ichnos Glenmark Innovation to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Ichnos Glenmark Innovation's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Top revenue contributor (30% of company revenue) but post-LOE generic with limited growth potential; generates stable cash to fund pipeline.
Help build intelligence for Ichnos Glenmark Innovation
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Second-largest revenue source approaching loss of exclusivity; dual indication in lipid and glycemic control provides stability but limited differentiation.
At peak revenue with patent protection extending to January 2033; among the more defensible assets in the portfolio with longest remaining exclusivity.
Post-LOE generic with specialty immunology mechanism; smaller revenue base supports niche positioning in autoimmune/dermatologic indications.
Post-LOE respiratory generic with minimal revenue contribution; consistent with respiratory therapeutic area focus but limited upside.
Specialty indication in substance use disorder addresses underserved neurology/psychiatry space but generates minimal revenue.
Topical antibiotic for skin infections; post-LOE generic with niche dermatology positioning and modest revenue.
Post-LOE cardiovascular generic addressing company's cardiovascular therapeutic focus but with minimal differentiation or growth.
Dermatology-focused topical generic with low-to-medium potency positioning; post-LOE with limited revenue but supports specialty dermatology platform.
74 discontinued, 101 duplicate formulations not shown
+1 more products with revenue data
Glenmark's innovation arm develops new candidate for cancer treatment - BioSpectrum India
Glenmark's innovation arm develops new candidate for cancer treatment BioSpectrum India
Glenmark Pharma's biotech arm IGI unveils ISB 2301 to target solid tumors - scanx.trade
Glenmark Pharma's biotech arm IGI unveils ISB 2301 to target solid tumors scanx.trade
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
+102 more products
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo